Bottom Line: Restricted scope
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.THE 170p flotation price for Goldsborough Healthcare borders on the expensive but has left enough room to ensure a small first day premium.
Assuming Goldsborough had been listed for the year to 2 October, the prospective p/e is 14.8 if it makes pounds 6.55m pre-tax. The rating is one to 1.5 points below its main sectoral rivals such as CrestaCare and Quality Care.
Investors should, however, be aware that the business is of a capital intensive nature. Goldsborough already enjoys occupancy levels of 95 per cent at its 26 homes, restricting the scope for organic growth and making acquisitions a necessity.
While the flotation raises pounds 29m of new money, Goldsborough will start with 15 per cent gearing, which will swiftly rise beyond 50 per cent. A cash call on investors to fund acquisitions could be made as soon as the end of 1995.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments